Talk:Rimonabant

Side effects section
Not happy with this section - "Because the drug has the opposite effects of cannabinoid receptor agonists such as tetrahydrocannabinol, which is neuroprotective against excitotoxicity,[6] it can be theorized that Rimonabant promotes the development of neurodegenerative diseases of the central nervous system such as Multiple sclerosis, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), Parkinson's disease, and Huntington's disease in persons who are susceptible.[7] The reported development of previously clinically silent multiple sclerosis in one patient taking Rimonabant suggests that any patients with an underlying neurological condition should not take Rimonabant, given the neuroprotective role of the endocannabinoid system in many experimental paradigms of neurological disease." I feel it ought to get a source that's more recent than 2002, and more accessible online, to boot. The relationship between the endocannabinoid system and Huntingdon's, vs its relationship with Alzheimer's, appear to be quite different. Note also that simply saying 'it has the opposite effects of [thc]' may be oversimplifying things. Without justifying that THC 'cures' all these ailments, you can't imply that rimonabant makes them worse. As for being opposite: yes, at the receptor, their effects are 'opposed', but who's to say what feed-foward or feedback there in the system? hard to assume that the response to stimulation or blocking of the receptor are parallel. Systems biology teaches us that's not often so. Philbradley (talk) 03:35, 19 March 2008 (UTC)

Can someone add a redirect then remove this note?
I don't know how to add redirects. I read about this drug but the spelling was "Rimonobant". I searched it here and of course didn't find it. Can someone add a redirect as I don't know how. Thanks. (Dave -- Dagenham, UK)


 * Done (that spelling gets a lot of Google hits!). Just FYI, anonymous users can't make redirects since they count as new pages. --Galaxiaad 03:42, 13 March 2007 (UTC)
 * Also added Slimona and Rimoslim redirects. Mendaliv (talk) 22:51, 12 March 2008 (UTC)

rimonabant-acomplia.de - NOT SPAM
Dear JanesDaddy and other users The link above points to a website I have just recently created. This website is intended to give independent information about Rimonabant and Acomplia; the idea is to have an plattform, where users or potential users share their ideas about the diet pill. This page has no intention to devaluate the drug or the Sanofi-Aventis in any form! I am putting information togehter right now and I am inviting people to help me getting information on the page so I would appreciate your consideration to maintain the link on this page; suggestions and feedback will be well received! --Coladose 09:40, 6 July 2006 (UTC)

It may not be spam, but it is not appropriate for the English language Wikipedia, but rather for the German language Wikipedia. You should create a content article in that Wikipedia (if there is not one) and create a language interlink. See Interlanguage links.75.2.16.36 10:54, 6 July 2006 (UTC)

THANKS FOR THE Advice, will get right to it! ;-) --Coladose 11:01, 6 July 2006 (UTC)

Keep SPAM out of here
Suspect same SPAMmer (24.21.40.18) as before (67.168.242.111) - BOTH COMCAST CUSTOMERS FROM OREGON, posting links to fake blogs with link SPAM and other depricated things. If you want to make a USEFUL contribution, please log in. JanesDaddy 00:36, 28 November 2005 (UTC)

Blogger.com account reported to Google for TOS violation. Hopefully this will go away soon. JanesDaddy 05:36, 28 November 2005 (UTC)

Method of action?
How and why does blocking a cannaboid receptor reduce appetite? Thanks!


 * I personally feel that this needs clarification. I am a student of pharmacology.  This resource and others tend to note rimonbant as a blocker or an antagonist at the CB1 receptor.  There is evidence to suggest that it is not a blocker but a inverse agonist.  Reverse agonists are G proteins which binds to the same receptor as previously identified agonists (in this case delta9 THC) and has reverse efficasy or a reverse effect.)  Whereas normal agonism of this receptor would generate the munchies, this keeps people from wanting to eat.  Further research by a friend and colleague suggest that rimonabant also effect the generation of memories (much like regular agonism).  This is a primary concern I have with this drug and what may be holding up FDA approval.
 * I do feel that it will be approved however because the government can flood the market with this drug and users of this would not be able to get high from marijuana when this drug is on board.--Carlwfbird 00:15, 22 September 2006 (UTC)


 * One source to classify drug as an inverse agonist.



Personal Attacks
Rkwkkr: Please note that, per WP:EL, some external links are permitted. These include substantive links with regular updates. Your site is not; Acomplia Resources is (it is used as a Google News feed, apparently). Also, please refrain in the future from personal attacks. Lastly, please sign your talk pages with four tildes.Link Spam Remover 23:20, 4 July 2006 (UTC)

"Acomplia Resources" is a "Made for AdSense" spam website
Sure, it offers some "content" but it is designed specifically to enrich its owner. It does not appear in Google News. Because DrPitroski has hijacked this page, he is prohibiting other sites that are more authoritative from appearing. He even deleted the link to the official Dutch Website (http://www.rimonabant.nl)

Saying he is a "Page Hijacker" isn't a personal attack...it's just stating an obvious fact. And, I believe I have the right to dispute the "neutrality" of the External Links. Note I didn't delete the link to the "spam website"...but people have the right to know what's going on.

Either that website should go, or other relevant content sites should be included.Rkwwkr

Apologies; your latest vandalism was not linkspam, but POV. DrPiotroski should comment on your accusations. And foreign language sites are not appropriate in the English version of Wikipedia. I will ask an admin (which I am not) to look at this matter. In the meantime, please desist. Link Spam Remover 15:08, 5 July 2006 (UTC)

Yeah, it is obvious that the website was made to enrich the owner. I like how they try to sidestep around the most common use of the CB1 receptor in giving an introduction to the drug. --Carlwfbird 00:19, 22 September 2006 (UTC)

Admin? Where's The Admin?
I'm getting tired of watching this page get hijacked by one narrow-minded intolerant poster. In Wikipedia, EVERYONE has the right and privilege to contribute, not just one person. If an admin doesn't step in, I will continue to fight against this page hijacking. Rkwwkr


 * Jeezes guys... Its almost as if the external link section is more important than the actual article... Rkwwkr I understand your frustration but please refrain from namecalling. I think we all do what we do in good faith... I personally think this section is best kept very short! --Steven Fruitsmaak 11:35, 16 July 2006 (UTC)

Chemical background
The article lacks some basic facts on how this molecule entered clinical development. Dabigatran and varenicline are two drugs where I've managed to trace, without much difficulty, how drug companies identified the relevant compounds. JFW | T@lk  21:10, 4 October 2006 (UTC)

Cannabinoid?
Is this or is this not a cannabinoid? There has been a bit of a revert war going on. Is there an expert who can positively say one way or another? -- Scjessey 21:13, 16 November 2006 (UTC)

In scientific literature all molecules (natural and synthetic cannabinoids, cannabinoid agonists and antagonists) that bind to cannabinoid receptors are considered to be cannabinoids. SR141716 (rimonabant) is very potent and selective cannabinoid ligand and is able to bind with high affinity to the CB1 cannabinoid receptor. Although SR141716 is cannabinoid receptor antagonist (or reverse agonist) it can be regarded as cannabinoid.--Tanevala 14:18, 19 November 2006 (UTC)

More on "Acomplia Resources"
This continues to be re-inserted into the page, yet it is a site designed to enrich its owner rather than provide useful information. Note the similarities, for example, between Zimulti Resources, Rimonabant Resources and Acomplia Resources. -- Scjessey 16:39, 18 November 2006 (UTC)

Where are the citations for Side Effects?
There is no citation for the "Reports of severe depression are frequent" claim made in the Side Effects secion. I'd like some evidence of this, someone please provide a link? —The preceding unsigned comment was added by Swampfoot (talk • contribs) 19:34, 15 February 2007 (UTC). http://www.tagesschau.de/aktuell/meldungen/0,,OID6010180,00.html


 * As a member of the original clinical trials in AZ, I can attest to some of the side effects. Ironically, weight loss was a side effect. The original trial was smoking cessation. Which, by the way, worked VERY well. But, as with all things, the money to be made was in losing weight easily I suppose. 2600:1700:1609:6810:81D6:7260:C4E3:E966 (talk) 15:48, 10 January 2024 (UTC)

Some changes
-- Panoramix303 09:30, 7 November 2007 (UTC)
 * The section about Memory was removed. It is too speculative and there are no hints from animal experiments so far (11/2007)
 * Ethanol and Cocaine addiction was merged. Rimonabant acts in both cases in the same way
 * A section about the blockade of THC-effects was added


 * There are animal experiments saying that it improves memory. It makes sense for a CB1 antagonist.. "Results show that performance on trials with delay intervals longer than 10 s was facilitated by rimonabant (2.0 mg/kg) owing to a significantly increased frequency of trials with stronger SmR codes. In contrast, WIN-2 (0.35 mg/kg) suppressed the strength of SmR codes necessary to perform trials with delays greater than 10 s."

http://www.ncbi.nlm.nih.gov/sites/entrez?Db=pubmed&Cmd=ShowDetailView&TermToSearch=17762525&ordinalpos=3&itool=EntrezSystem2.PEntrez.Pubmed.Pubmed_ResultsPanel.Pubmed_RVDocSum Wanna put the memory section back with source? Miserlou 00:51, 8 November 2007 (UTC)

The section is back with the reference. Thanks for the link to the article. I somehow missed it.... -- Panoramix303 06:59, 8 November 2007 (UTC)

RIO
I'm moving this here until somebody makes it legible.

RIO program
section Unreferencedsection
 * RIO EUROPE : N = 1507; BMI >= 30kg/m2 or >=27kg/m2 with comorbidity, Duration 1 year
 * RIO Diabetes : N = 1045; BMI 27–40 kg/m2 and type 2 diabetes, Duration 1 year
 * RIO LIPIDS : N = 1033; BMI 27–40 kg/m2 and dyslipidemia Duration 1 year
 * RIO NORTH AMERICA : N = 3045; BMI ≥30 kg/m2 or >27 kg/m2 with comorbidity, Duration 2 years